Mumbai, March 3, 2026: Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), a unit of Tata Memorial Centre, are advancing the future of cancer care in India by bringing next-generation Spectral CT imaging, reinforcing shared commitment to more precise diagnosis, enabling earlier disease detection, and improving clinical decision-making for patients with complex cancers.

As India faces a growing burden of cancer and complex multi-system diseases, timely and accurate diagnosis has never been more critical. Diagnostic delays can contribute to avoidable patient harm, while repeat imaging may increase radiation exposure, patient anxiety, and treatment timelines — particularly in high-volume tertiary care centres.

Philips Spectral CT 7500 enables clinicians to capture detailed spectral information during routine CT scans. This allows for deeper disease characterisation from a single scan, helping clinicians make earlier, more confident diagnostic decisions without increasing radiation dose. It provides richer insight from a single scan, reducing repeat imaging and enabling full body exams in approximately two seconds. Studies also show 36% fewer additional diagnostic procedures in complex cancer evaluations, directly reducing patient anxiety, radiation exposure and overall treatment delays.

Bharath Sesha, Managing Director, Philips Indian Subcontinent, said, “At Philips, we are committed to enabling precision diagnosis by providing advanced imaging capabilities to leading healthcare institutions. Our collaboration with Tata Memorial Cancer Centre demonstrates how technology can support clinicians in making faster, more accurate decisions, while enhancing patient safety and workflow efficiency. By embedding Spectral CT into routine practice, we aim to help healthcare teams reduce delays, minimise unnecessary scans and improve access to timely diagnosis — supporting India’s broader goal of strengthening diagnostic infrastructure and improving outcomes.”

Dr. Pankaj Chaturvedi, Director, ACTREC, Tata Memorial Centre, said, “Accurate and timely diagnosis is the cornerstone of effective cancer care. The commissioning of advanced Spectral CT at ACTREC reflects our commitment to integrating cutting-edge technology into clinical practice for the direct benefit of our patients. By enabling deeper diagnostic insights from a single scan while improving efficiency, this platform will help clinicians make faster, more informed treatment decisions. We dedicate this technology to the service of our patients and reaffirm our mission to advance cancer care through innovation that is precise, compassionate, and future-ready.”

The introduction of Spectral CT will support multiple clinical specialties including oncology, cardiology, neurology and emergency care, areas where rapid and confident assessment is critical to improving outcomes. During a joint clinical program on Spectral CT held at ACTREC on February 7, 2026, ‘Spectral CT: Clinical Publication Compendium’ was unveiled in the presence of leading radiologists. The compendium brings together over 770 peer-reviewed publications and white papers from across the globe, demonstrating how always-on detector-based spectral CT delivers higher diagnostic certainty, optimized dose and contrast, reduced follow-up examinations, and improved workflow efficiency across a wide range of clinical applications.

Philips remains committed to advancing India’s diagnostic ecosystem, ensuring that patients benefit from greater clarity, reduced delays and a more streamlined experience at the start of their treatment journey. As one of India’s leading comprehensive cancer centres, ACTREC continues to adopt advanced technologies that meaningfully enhance patient care while supporting the evolution of oncology practice nationwide.